Markers of Bone Turnover for the Prediction of Fracture Risk and Monitoring of Osteoporosis Treatment: a Need for International Reference Standards

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2010 Dec 25

PMID 21184054

Citations 424

Authors

S Vasikaran

R Eastell

O Bruyere

A J Foldes

P Garnero

A Griesmacher

M McClung

H A Morris

S Silverman

T Trenti

D A Wahl

C Cooper

J A Kanis

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies.

Introduction: Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda.

Methods: Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001.

Results: High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine.

Conclusion: BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards.

Citing Articles

Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women.

Bailly A, Hester G, Alesi M, Buresh R, Feito Y, Mermier C J Bone Miner Metab. 2025; .

PMID: 40053115 DOI: 10.1007/s00774-025-01592-0.

Bone turnover markers are risk factors for endplate injuries during lumbar interbody fusion: a retrospective case-control study.

Kang T, Chung S, Seo I, Cho M, Lee J J Orthop Surg Res. 2025; 20(1):192.

PMID: 39987433 PMC: 11847339. DOI: 10.1186/s13018-025-05585-7.

Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.

Tan Y, Liu S, Tang Q Acta Diabetol. 2025; .

PMID: 39985672 DOI: 10.1007/s00592-025-02468-5.

Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials.

Ma T, Zhang T, Zhang L, Zhao H, Liu K, Kuang J J Orthop Surg Res. 2025; 20(1):127.

PMID: 39891296 PMC: 11786478. DOI: 10.1186/s13018-025-05513-9.

Activity of Selected Bone Formation and Angiogenesis Markers During the Treatment of Limb Length Discrepancy in Children Using Distraction Osteogenesis with the Circular Hexapod External Fixator.

Sygacz O, Miazga D, Skorupa A, Stec S, Matuszewska J, Kreft R J Clin Med. 2025; 14(2).

PMID: 39860546 PMC: 11765507. DOI: 10.3390/jcm14020540.

References

Civitelli R, Armamento-Villareal R, Napoli N . Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20(6):843-51. DOI: 10.1007/s00198-009-0838-9. View

Bauer D, Garnero P, Hochberg M, Santora A, Delmas P, Ewing S . Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006; 21(2):292-9. DOI: 10.1359/JBMR.051018. View

de Papp A, Bone H, Caulfield M, Kagan R, Buinewicz A, Chen E . A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone. 2007; 40(5):1222-30. DOI: 10.1016/j.bone.2007.01.008. View

Muller M . Implementation of reference systems in laboratory medicine. Clin Chem. 2000; 46(12):1907-9. View

Szulc P, Delmas P . Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008; 19(12):1683-704. DOI: 10.1007/s00198-008-0660-9. View

Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W . A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007; 40(5):1238-43. DOI: 10.1016/j.bone.2007.01.016. View

Stenman U . Standardization of assays for human chorionic gonadotropin. Clin Chem. 2004; 50(5):798-800. DOI: 10.1373/clinchem.2003.031013. View

Riis B, Hansen M, Jensen A, Overgaard K, Christiansen C . Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone. 1996; 19(1):9-12. DOI: 10.1016/8756-3282(96)00102-0. View

Adami S, Bianchi G, Brandi M, Giannini S, Ortolani S, DiMunno O . Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int. 2008; 82(5):341-7. DOI: 10.1007/s00223-008-9126-5. View

10.

Chen P, Satterwhite J, Licata A, Lewiecki E, Sipos A, Misurski D . Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20(6):962-70. DOI: 10.1359/JBMR.050105. View

11.

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

12.

Rosen C, Chesnut 3rd C, Mallinak N . The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997; 82(6):1904-10. DOI: 10.1210/jcem.82.6.4004. View

13.

Morris H . Traceability and standardization of immunoassays: a major challenge. Clin Biochem. 2009; 42(4-5):241-5. DOI: 10.1016/j.clinbiochem.2008.09.005. View

14.

Christiansen C, Riis B, RODBRO P . Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int. 1990; 1(1):35-40. DOI: 10.1007/BF01880414. View

15.

Maclean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M . Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2007; 148(3):197-213. DOI: 10.7326/0003-4819-148-3-200802050-00198. View

16.

Hannon R, Eastell R . Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int. 2001; 11 Suppl 6:S30-44. DOI: 10.1007/s001980070004. View

17.

Darby A, Meunier P . Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int. 1981; 33(3):199-204. DOI: 10.1007/BF02409438. View

18.

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View

19.

McKiernan F, Berg R, Linneman J . The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis. Osteoporos Int. 2010; 22(4):1069-77. DOI: 10.1007/s00198-010-1307-1. View

20.

Seibel M, Lang M, Geilenkeuser W . Interlaboratory variation of biochemical markers of bone turnover. Clin Chem. 2001; 47(8):1443-50. View